<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A left ventricular assist system (LVAS, Toyobo CO., LTD., Japan) was used to provide life support for 190 days in a 44-year-old male patient with end-stage <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Before LVAS implantation, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and cardiogenic shock with multi-organ dysfunction progressed despite the use of intra-aortic balloon pumping (18 days), mechanical ventilatory support (15 days), continuous veno-venous hemofiltration (two days) and intravenous administration of <z:chebi fb="2" ids="33567">catecholamines</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Before LVAS implantation, the patient had marked hepatic and <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> (total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> 6.1, BUN 73 and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> 3.1 mg/dl) </plain></SENT>
<SENT sid="3" pm="."><plain>Those functions returned to <z:mpath ids='MPATH_458'>normal</z:mpath> (total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> 1.2, BUN 11 and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> 0.6 mg/dl) one month after implantation </plain></SENT>
<SENT sid="4" pm="."><plain>He was complicated by multiple <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolisms</z:e> occurring on the 9th, 57th and 175th postoperative days and died 190 days after surgery </plain></SENT>
<SENT sid="5" pm="."><plain>Autopsy showed <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> attaching to the diaphragm of the blood pump and multiple embolisms in the kidney and the spleen </plain></SENT>
<SENT sid="6" pm="."><plain>By scanning electron microscopic examination, initial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> with attached erythrocytes were seen on the diaphragm surface without intimal lining formation </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, LVAS support can be useful for patients with <z:e sem="disease" ids="C0919984" disease_type="Disease or Syndrome" abbrv="">end-stage heart disease</z:e> complicated by multi-organ dysfunction </plain></SENT>
<SENT sid="8" pm="."><plain>However, the LVAS may cause thromboembolic complications over the prolonged use </plain></SENT>
</text></document>